Asia
PDC*line Pharma grants exclusive license in South Korea and exclusive option in other Asian countries to LG Chem Life Sciences Company, for the development and commercialization of PDC*lung cancer vaccine for lung cancer
MorphoSys AG andI-Mab Biopharma announced that the first patient has been dosed in a phase 2 clinical study in Taiwan to evaluate MorphoSys’s investigational human CD38 antibody TJ202/MOR202 in patients with relapsed or refractory multiple myeloma.
Biotech and pharma companies from across Europe and Asia provide updates on pipeline and business activities.
Vejthani Hospital, one of the leading hospitals specializing in bone and joint treatment in Thailand, called on patients suffering from complications caused by diseases such as diabetes to regularly care for their health and practice self-monitoring, including taking care of their wounds and checking their nervous system, to prevent the occurrence of Charcot foot.
In the wake of the scandal caused by a Chinese researcher’s use of CRISPR-Cas9 gene editing to alter the DNA of embryos for seven couples, leading scientists called for a moratorium on heritable genome editing.
In addition to the planned BioNTech IPO, many other pharma and biotech companies in Europe, Asia and elsewhere shared news for the week.
The FDA issues Warning Letters to biopharma, medical device and food companies when they find that a manufacturer has significantly violated FDA regulations. As of March 4, the agency issued 45 Warning Letters this year.
TLC Reports Positive Top-Line Results from Phase I/II Clinical Trial of TLC590 for Postsurgical Pain
TLC590 demonstrated durable, statistically significant and clinically meaningful improvement over the standard of care through 96 hours
UAE’s AED 4.40 billion healthcare allocation for 2019 seen to further drive growth in digital healthcare
Takeda Pharmaceutical’s Entyvio outperformed AbbVie’s Humira in a head-to-head comparison in treating ulcerative colitis during a late-stage study, the company said.
PRESS RELEASES